Selection and characterization of human respiratory syncytial virus escape mutants resistant to a polyclonal antiserum raised against the F protein

Archives of Virology

Volumn 157, Issue 6, 2012, Pages 1071-1080

  Tomé, Lorena ^a,b   Frabasile, Sandra ^a   Candia, Claudia ^a   Pittini, Alvaro ^a   Farina, Natalia ^a   Melero, José Antonio ^c   Arbiza, Juan ^a  

^a UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

^b INSTITUT PASTEUR DE MONTEVIDEO   (Uruguay)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

F PROTEIN, HUMAN RESPIRATORY SYNCYTIAL VIRUS; VIRUS ANTIBODY; VIRUS FUSION PROTEIN;

ARTICLE; CELL STRAIN HEPG2; CHEMISTRY; GENETICS; HUMAN; IMMUNE EVASION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MISSENSE MUTATION; PROTEIN MOTIF; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SERODIAGNOSIS; VIROLOGY;

AMINO ACID MOTIFS; ANTIBODIES, VIRAL; HEP G2 CELLS; HUMANS; IMMUNE EVASION; MUTATION, MISSENSE; NEUTRALIZATION TESTS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VIRAL FUSION PROTEINS;

HUMAN RESPIRATORY SYNCYTIAL VIRUS; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 84861790336     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-012-1274-2     Document Type: Article

References (53)

1. Cane PA (2001) Molecular epidemiology of respiratory syncytial virus. Rev Med Virol 11: 103-116.
2. Collins PL, McIntosh K, Chanock RM (1996) Respiratory syncytial virus. In: Fields BN, Knipe DM, Howley PM (eds) Fields virology, 3rd edn. Lippincott-Raven, Philadelphia, pp 1313-1351.
3. Gardner PS (1973) Respiratory syncytial virus infections. Postgrad Med J 49: 788-791.
4. Murphy BR, Prince GA, Collins PL, van Wyke Coelingh K, Olmsted RA, Spriggs MK, Parrott RH, Kim HW, Brandt CD, Chanock RM (1988) Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses. Virus Res 11: 1-15.
5. Parrott RH, Kim HW, Arrobio JO, Hodes DS, Murphy BR, Brandt CD, Camargo E, Chanock RM (1973) Epidemiology of respiratory syncytial virus infection in Washington, D. C. II. Infection and disease with respect to age, immunologic status, race and sex. Am J Epidemiol 98: 289-300.
6. Englund (1999) Prophylaxis and therapy of RSV and other community respiratory virus infections in immunocompromised hosts. Cancer Res Ther Control 9: 141-145.
7. Han LL, Alexander JP, Anderson LJ (1999) Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J Infect Dis 179: 25-30.
8. Murry AR, Dowell SF (1997) Respiratory syncytial virus: not just for kids. Hosp Pract 32: 87-88, 91-84, 98 passim.
9. Wendt CH, Hertz MI (1995) Respiratory syncytial virus and parainfluenza virus infections in the immunocompromised host. Semin Respir Infect 10: 224-231.
10. Elango N, Prince GA, Murphy BR, Venkatesan S, Chanock RM, Moss BR (1986) Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein. Proc Natl Acad Sci USA 83: 1906-1910.
11. Johnson PR Jr, Olmsted RA, Prince GA, Murphy BR, Alling DW, Walsh EE, Collins PL (1987) Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. J Virol 61: 3163-3166.
12. Olmsted RA, Elango N, Prince GA, Murphy BR, Johnson PR, Moss B, Chanock RM, Collins PL (1986) Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc Natl Acad Sci USA 83: 7462-7466.
13. Walsh EE, Brandriss MW, Schlesinger JJ (1987) Immunological differences between the envelope glycoproteins of two strains of human respiratory syncytial virus. J Gen Virol 68: 2169-2176.
14. Wertz GW, Stott EJ, Young KK, Anderson K, Ball LA (1987) Expression of the fusion protein of human respiratory syncytial virus from recombinant vaccinia virus vectors and protection of vaccinated mice. J Virol 61: 293-301.
15. Scheid A, Choppin PW (1977) Two disulfide-linked polypeptide chains constitute the active F protein of paramyxoviruses. Virology 80: 54-66.
16. Walsh EE, Hruska J (1983) Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein. J Virol 47: 171-177.
17. Collins PL, Mottet G (1991) Post-translational processing and oligomerization of the fusion glycoprotein of human respiratory syncytial virus. J Gen Virol 72(Pt 12): 3095-3101.
18. Gruber C, Levine S (1983) Respiratory syncytial virus polypeptides. III. The envelope-associated proteins. J Gen Virol 64(Pt 4): 825-832.
19. Gonzalez-Reyes L, Ruiz-Arguello MB, Garcia-Barreno B, Calder L, Lopez JA, Albar JP, Skehel JJ, Wiley DC, Melero JA (2001) Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion. Proc Natl Acad Sci USA 98: 9859-9864.
20. Bolt G, Pedersen LO, Birkeslund HH (2000) Cleavage of the respiratory syncytial virus fusion protein is required for its surface expression: role of furin. Virus Res 68: 25-33.
21. Arbiza J, Taylor G, Lopez JA, Furze J, Wyld S, Whyte P, Stott EJ, Wertz G, Sullender W, Trudel M, Melero JA (1992) Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. J Gen Virol 73(Pt 9): 2225-2234.
22. Lopez JA, Bustos R, Orvell C, Berois M, Arbiza J, Garcia-Barreno B, Melero JA (1998) Antigenic structure of human respiratory syncytial virus fusion glycoprotein. J Virol 72: 6922-6928.
23. Garcia-Barreno B, Palomo C, Penas C, Delgado T, Perez-Brena P, Melero JA (1989) Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins. J Virol 63: 925-932.
24. Lopez JA, Andreu D, Carreno C, Whyte P, Taylor G, Melero JA (1993) Conformational constraints of conserved neutralizing epitopes from a major antigenic area of human respiratory syncytial virus fusion glycoprotein. J Gen Virol 74(Pt 12): 2567-2577.
25. Beeler JA, van Wyke Coelingh K (1989) Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 63: 2941-2950.
26. Lopez JA, Penas C, Garcia-Barreno B, Melero JA, Portela A (1990) Location of a highly conserved neutralizing epitope in the F glycoprotein of human respiratory syncytial virus. J Virol 64: 927-930.
27. Zhao X, Chen FP, Megaw AG, Sullender WM (2004) Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants. J Infect Dis 190: 1941-1946.
28. Zhao X, Sullender WM (2005) In vivo selection of respiratory syncytial viruses resistant to palivizumab. J Virol 79: 3962-3968.
29. Zhao X, Liu E, Chen FP, Sullender WM (2006) In vitro and in vivo fitness of respiratory syncytial virus monoclonal antibody escape mutants. J Virol 80: 11651-11657.
30. Sullender WM, Edwards KG (1999) Mutations of respiratory syncytial virus attachment glycoprotein G associated with resistance to neutralization by primate polyclonal antibodies. Virology 264: 230-236.
31. Walsh EE, Brandriss MW, Schlesinger JJ (1985) Purification and characterization of the respiratory syncytial virus fusion protein. J Gen Virol 66(Pt 3): 409-415.
32. Carrillo EC, Rieder Rojas E, Cavallaro L, Schiappacassi M, Campos R (1989) Modification of Foot-and-Mouth disease virus after serial passages in the presence of antiviral polyclonal sera. Virology 171: 599-601.
33. Schiappacassi M, Rieder Rojas E, Carrillo E, Campos R (1995) Response of foot-and-mouth disease virus C3 Resende to immunological pressure exerted in vitro by antiviral polyclonal sera. Virus Res 36: 77-85.
34. McKimm-Breschkin JL (2004) A simplified plaque assay for respiratory syncytial virus-direct visualization of plaques without immunostaining. J Virol Methods 120: 113-117.
35. Martinez I, Dopazo J, Melero JA (1997) Antigenic structure of the human respiratory syncytial virus G glycoprotein and relevance of hypermutation events for the generation of antigenic variants. J Gen Virol 78(Pt 10): 2419-2429.
36. Garcia-Barreno B, Delgado T, Akerlind-Stopner B, Norrby E, Melero JA (1992) Location of the epitope recognized by monoclonal antibody 63G on the primary structure of human respiratory syncytial virus G glycoprotein and the ability of synthetic peptides containing this epitope to induce neutralizing antibodies. J Gen Virol 73(Pt 10): 2625-2630.
37. Taylor G, Stott EJ, Bew M, Fernie BF, Cote PJ, Collins AP, Hughes M, Jebbett J (1984) Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology 52: 137-142.
38. Trudel M, Nadon F, Seguin C, Payment P, Talbot PJ (1987) Respiratory syncytial virus fusion glycoprotein: further characterization of a major epitope involved in virus neutralization. Can J Microbiol 33: 933-938.
39. Hall T (1999) BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 41: 95-98.
40. Buchholz UJ, Finke S, Conzelmann KK (1999) Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J Virol 73: 251-259.
41. Zimmer G, Trotz I, Herrler G (2001) N-glycans of F protein differentially affect fusion activity of human respiratory syncytial virus. J Virol 75(Pt 10): 4744-4751.
42. Taylor G, Stott EJ, Furze J, Ford J, Sopp P (1992) Protective epitopes on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies. J Gen Virol 73(Pt 9): 2217-2223.
43. McLellan JS, Chen M, Kim A, Yang Y, Graham BS, Kwong PD (2010) Structural basis of respiratory syncytial virus neutralization by motavizumab. Nat Struct Mol Biol 17: 248-250.
44. McLellan JS, Yang Y, Graham BS, Kwong PD (2011) Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol 85: 7788-7796.
45. Swanson KA, Settembre EC, Shaw CA, Dey AK, Rappuoli R, Mandl CW, Dormitzer PR, Carfi A (2011) Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci USA 108: 9619-9624.
46. Palomo C, Garcia-Barreno B, Penas C, Melero JA (1991) The G protein of human respiratory syncytial virus: significance of carbohydrate side-chains and the C-terminal end to its antigenicity. J Gen Virol 72(Pt 3): 669-675.
47. Adams O, Bonzel L, Kovacevic A, Mayatepek E, Hoehn T, Vogel M (2010) Palivizumab-resistant human respiratory syncytial virus infection in infancy. Clin Infect Dis 51: 185-188.
48. Zhu Q, Patel NK, McAuliffe J, Zhu W, Wachter L, McCarthy M, Suzich J (2011) Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): effects on RSV susceptibility to palivizumab. J Inf Dis Dec 19: 1-4.
49. Boivin G, Caouette G, Frenette L, Carbonneau J, Ouakki M, De Serres G (2008) Human respiratory syncytial virus and other viral infections in infants receiving palivizumab. J Clin Virol 42(Pt 1): 52-57.
50. Reitz MS, Wilson C, Naugle C, Gallo RC, Robert-Guroff M (1988) Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene. Cell 54: 57-63.
51. Bissonnette ML, Donald JE, DeGrado WF, Jardetzky TS, Lamb RA (2009) Functional analysis of the transmembrane domain in paramyxovirus F protein-mediated membrane fusion. J Mol Biol 386: 14-36.
52. Seth S, Goodman AL, Compans RW (2004) Mutations in multiple domains activate paramyxovirus F protein-induced fusion. J Virol 78: 8513-8523.
53. Zhao X, Chen FP, Sullender WM (2004) Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats. Virology 318: 608-612.